KIF22 Promotes Development of Pancreatic Cancer by Regulating the MEK/ERK/P21 Signaling Axis

Table 1

The relationship between KIF22 expression and clinicopathological features in patients with pancreatic cancer.

Clinicopathological characteristics	KIF22 high expression ()	KIF22 low expression ()	value
Age			0.733
Sex
Male	29 (65.91%)	18 (66.67%)	0.848
Female	15 (34.09%)	9 (33.33%)
CA 199			<0.0001
Ki67			<0.0001
≤25%	2 (4.55%)	16 (59.26%)
26%~50%	14 (31.82%)	10 (37.04%)
>50%	28 (63.64%)	1 (3.7%)
Pathological type
Ductal adenocarcinoma	25 (56.82%)	14 (51.85%)	0.683
Adenocarcinoma	19 (43.18%)	13 (41.15%)
Differentiation
Low differentiation	13 (29.55%)	10 (37.04%)	0.744
Moderate differentiation	26 (59.09%)	15 (55.56%)
High differentiation	5 (11.36%)	2 (7.41%)
AJCC pathological stage
II	10 (22.73%)	17 (62.96%)	0.013
III	18 (40.91%)	9 (33.33%)
IV	6 (36.36%)	1 (3.70%)
T stage
T1	2 (4.55%)	5 (18.52%)	0.001
T2	19 (43.18%)	20 (74.07%)
T3	13 (29.55%)	1 (3.7%)
T4	10 (22.73%)	1 (3.7%)
N stage
N0	13 (29.55%)	12 (44.44%)	0.05
N1	26 (59.09%)	10 (37.04%)
N2	5 (11.36%)	5 (18.52%)